Cathay Biotech Inc (688065) Fair Value & Analysis

Basic Materials · CN · Market cap 32.6B CNY

Analysis

Cathay Biotech Inc (688065) currently trades at ¥50.70, while our model-based Fair Value estimate is ¥13.33 — implying the stock looks roughly 73.7% overvalued today. We read business quality at 80/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for electrification, automation, and digitization for biological manufacturing. The company's products are used in textiles, pharmaceuticals, perfumes, automobiles, electronic appliances, consumer goods, engineering materials, and other industries. It exports its products. The company was incorporated in 2000 and is headquartered in Shanghai, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.